Q-omics provides the consensus-scored MED15P9 profile across patient tissues and cancer cell-line models. MED15P9 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, MED15P9 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, MED15P9 RNA expression shows 9,501 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, BRCA, and THYM as cancer lineages where MED15P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MED15P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MED15P9 survival associations across molecular data types. MED15P9 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MED15P9 RNA expression–survival associations across cancer types. High MED15P9 expression shows unfavorable associations in LUAD, COAD, KIRP and ACC, but favorable associations in PAAD and ESCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for MED15P9 RNA expression.
This table summarizes MED15P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MED15P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MED15P9 shows higher tumor expression in BRCA, LUSC and UCEC. The BRCA box plot shows higher MED15P9 RNA expression in tumor versus normal tissue (log2 FC = +0.098, t-test p = .015).
This table shows molecular features associated with MED15P9 in patient tissues and cancer cell lines. In patient samples, MED15P9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
